ライフサイエンスコーパス: emtricitabine

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 favirenz, tenofovir disoproxil fumarate, and emtricitabine).

2 daily oral tenofovir disoproxil fumarate and emtricitabine.

3 6%; 95% CI, 0.03% to 1.1%) had tenofovir and emtricitabine.

4 h zidovudine or tenofovir plus lamivudine or emtricitabine.

5 nofovir and 212.5 ng/mL (140.0 to 405.0) for emtricitabine.

6 y dose of tenofovir disoproxil fumarate plus emtricitabine.

7 ormulated tenofovir disoproxil fumarate plus emtricitabine.

8 mivudine than those including tenofovir plus emtricitabine.

9 CI 1.08-1.98) and negatively associated with emtricitabine (0.67, 95% CI 0.46-0.99).

10 up) or dolutegravir 50 mg with co-formulated emtricitabine 200 mg and tenofovir alafenamide 25 mg (th

11 5 mg or dolutegravir 50 mg with coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg, wi

12 r dolutegravir 50 mg given with coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg.

13 (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 mg/100 mg) for 28

14 T in pregnancy (once-daily tenofovir 300 mg, emtricitabine 200 mg, and efavirenz 600 mg) and achievin

15 ion of tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600 mg.

16 combination tenofovir alafenamide 25 mg and emtricitabine 200 mg, and once-daily oral dolutegravir 5

17 ion tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg, and once-daily oral dolutegravir 5

18 ning elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg (t

19 n of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg on

20 taining darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg, w

21 to receive co-formulated bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg (t

22 with either co-formulated bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg (t

23 , to receive coformulated bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or

24 al fixed-dose combination bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or

25 n to receive coformulated bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, o

26 imen) or tenofovir (245 mg once per day) and emtricitabine (200 mg once per day; standard regimen).

27 f tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) and advised to take one tablet pe

28 assign (1:1) participants to receive either emtricitabine (200 mg) and tenofovir alafenamide (25 mg)

29 itabine and tenofovir alafenamide group), or emtricitabine (200 mg) and tenofovir disoproxil fumarate

30 d tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) either immediately or after a def

31 elvitegravir (150 mg), cobicistat (150 mg), emtricitabine (200 mg), and tenofovir alafenamide (10 mg

32 ingle-tablet regimen of rilpivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg

33 ablet regimen of either rilpivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg

34 single-tablet regimen of efavirenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarat

35 ingle-tablet regimen of rilpivirine (25 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarat

36 s tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg).

37 ted TFV-DP in DBS following daily oral PrEP (emtricitabine 200mg/tenofovir diphosphate 300mg) among p

38 vir (MONCAY trial), or to continue tenofovir/emtricitabine + a third agent or switch to tenofovir/emt

39 bo plus the fixed-dose combination of 200 mg emtricitabine and 25 mg tenofovir alafenamide for 48 wee

40 ine combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil fumarate o

41 essed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted atazanavir (ATV) und

42 icipants were randomly assigned and received emtricitabine and tenofovir alafenamide (n=2694) or emtr

43 gravir group] and 330 with dolutegravir plus emtricitabine and tenofovir alafenamide [dolutegravir gr

44 udy drug to 98 (65 received bictegravir plus emtricitabine and tenofovir alafenamide and 33 received

45 INTERPRETATION: Bictegravir plus emtricitabine and tenofovir alafenamide and dolutegravir

46 Bictegravir co-formulated with emtricitabine and tenofovir alafenamide as a fixed-dose

47 tions-coformulated with the NRTI combination emtricitabine and tenofovir alafenamide as a fixed-dose

48 and safety of bictegravir coformulated with emtricitabine and tenofovir alafenamide as a fixed-dose

49 ompared with dolutegravir plus co-formulated emtricitabine and tenofovir alafenamide at week 96.

50 tenofovir alafenamide and dolutegravir plus emtricitabine and tenofovir alafenamide both showed high

51 One participant taking bictegravir plus emtricitabine and tenofovir alafenamide discontinued bec

52 iagnosed with HIV, seven participants in the emtricitabine and tenofovir alafenamide group (0.16 infe

53 ) of 65 participants in the bictegravir plus emtricitabine and tenofovir alafenamide group versus 22

54 dy drug (36 [1%] of 2694 participants in the emtricitabine and tenofovir alafenamide group vs 49 [2%]

55 tablets daily, with matched placebo tablets (emtricitabine and tenofovir alafenamide group), or emtri

56 rsus 22 (67%) of 33 in the dolutegravir plus emtricitabine and tenofovir alafenamide group.

57 Emtricitabine and tenofovir alafenamide had more favoura

58 Daily emtricitabine and tenofovir alafenamide shows non-inferi

59 Non-inferiority of emtricitabine and tenofovir alafenamide to emtricitabine

60 fety of pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir alafenamide versus emtricita

61 ted 48 weeks and 50% had completed 96 weeks) emtricitabine and tenofovir alafenamide was non-inferior

62 Emtricitabine and tenofovir alafenamide was superior to

63 lafenamide and 33 received dolutegravir plus emtricitabine and tenofovir alafenamide).

64 existing INSTI options with the backbone of emtricitabine and tenofovir alafenamide, might provide a

65 dolutegravir administered with coformulated emtricitabine and tenofovir alafenamide.

66 observed dosing of daily oral co-formulated emtricitabine and tenofovir disoproxil fumarate (FTC/TDF

67 tabine and tenofovir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693)

68 egimen) or ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate (proteas

69 n who has sex with men and had been on daily emtricitabine and tenofovir disoproxil fumarate for 8 mo

70 nd tenofovir alafenamide was non-inferior to emtricitabine and tenofovir disoproxil fumarate for HIV

71 tricitabine and tenofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate for HIV

72 enamide shows non-inferior efficacy to daily emtricitabine and tenofovir disoproxil fumarate for HIV

73 % CI 0.06-0.33]), and 15 participants in the emtricitabine and tenofovir disoproxil fumarate group (0

74 group vs 49 [2%] of 2693 participants in the emtricitabine and tenofovir disoproxil fumarate group).

75 tablets daily, with matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate group).

76 ne and tenofovir alafenamide was superior to emtricitabine and tenofovir disoproxil fumarate in all s

77 Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highl

78 nucleoside reverse transcriptase inhibitors: emtricitabine and tenofovir disoproxil fumarate or abaca

79 f emtricitabine and tenofovir alafenamide to emtricitabine and tenofovir disoproxil fumarate was esta

80 ts with current or previous use of PrEP with emtricitabine and tenofovir disoproxil fumarate were not

81 ith a third regimen (efavirenz combined with emtricitabine and tenofovir disoproxil fumarate) previou

82 an efavirenz regimen (both regimens include emtricitabine and tenofovir disoproxil fumarate).

83 pe HIV-1 infection despite consistent use of emtricitabine and tenofovir disoproxil fumarate.

84 regimen of ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate.

85 density and biomarkers of renal safety than emtricitabine and tenofovir disoproxil fumarate.

86 rEP programme with sexual event-based use of emtricitabine and tenofovir for MSM who had condomless a

87 vir plus either lamivudine and zidovudine or emtricitabine and tenofovir), versus zidovudine alone.

88 ate of at least 30 mL/min and sensitivity to emtricitabine and tenofovir.

89 , and HIV-1 genotypes showing sensitivity to emtricitabine and tenofovir.

90 ood donors in 6 US locations were tested for emtricitabine and tenofovir.

91 r combined tenofovir disoproxil fumarate and emtricitabine and whether the benefits vary by risk grou

92 0 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide.

93 Participants in the tenofovir alafenamide, emtricitabine, and dolutegravir group had fewer changes

94 1 participants in the tenofovir alafenamide, emtricitabine, and dolutegravir group, 275 (78%) of 351

95 domly assigned to the tenofovir alafenamide, emtricitabine, and dolutegravir group, 351 to the tenofo

96 [6.7] in the tenofovir disoproxil fumarate, emtricitabine, and dolutegravir group, and 2.3 kg [7.0]

97 ipants in the tenofovir disoproxil fumarate, emtricitabine, and dolutegravir group, and 258 (74%) of

98 p, 351 to the tenofovir disoproxil fumarate, emtricitabine, and dolutegravir group, and 351 to the te

99 .1 kg [SD 7.4] in the tenofovir alafenamide, emtricitabine, and dolutegravir group; 4.3 kg [6.7] in t

100 conception to tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (901 of 2472

101 ipants in the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group discontinued due to t

102 ipants in the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group had achieved a plasma

103 [7.0] in the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group), and was greater amo

104 nd 351 to the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group.

105 or ART (fixed-dose combination of tenofovir, emtricitabine, and efavirenz) regardless of CD4 cell cou

106 eive tenofovir-disoproxil fumarate (DF) plus emtricitabine, and either cobicistat-boosted elvitegravi

107 use of tenofovir disoproxil fumarate (TDF), emtricitabine, and lamivudine and potential transmission

108 onavir (zidovudine-based ART); or tenofovir, emtricitabine, and lopinavir-ritonavir (tenofovir-based

109 ndomly assigned to elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (n=111 [66%]) o

110 cipants to receive coformulated bictegravir, emtricitabine, and tenofovir alafenamide (n=316) or cofo

111 rolled and randomly assigned to bictegravir, emtricitabine, and tenofovir alafenamide (n=316) or dolu

112 TION: At 48 weeks, coformulated bictegravir, emtricitabine, and tenofovir alafenamide achieved virolo

113 assigned and treated (438 with rilpivirine, emtricitabine, and tenofovir alafenamide and 437 with ef

114 cacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide as a potential

115 These week 96 data support bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well

116 These week 96 data support bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well

117 ng-term data support the use of bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well

118 acy, safety and tolerability of bictegravir, emtricitabine, and tenofovir alafenamide compared with c

119 cy, safety, and tolerability of bictegravir, emtricitabine, and tenofovir alafenamide compared with d

120 ingle-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with r

121 Because coformulated bictegravir, emtricitabine, and tenofovir alafenamide does not requir

122 assigned to treatment (327 with bictegravir, emtricitabine, and tenofovir alafenamide fixed-dose comb

123 INTERPRETATION: Switching to rilpivirine, emtricitabine, and tenofovir alafenamide from efavirenz,

124 up and 273 (84%) of 325 in the dolutegravir, emtricitabine, and tenofovir alafenamide group (differen

125 versus six (2%) of 325 in the dolutegravir, emtricitabine, and tenofovir alafenamide group (study 2)

126 % (SD 3.27) in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group and -0.10

127 .33% (2.20) in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group and -0.73

128 ss than 50 copies per mL in the bictegravir, emtricitabine, and tenofovir alafenamide group and 265 (

129 ss than 50 copies per mL in the bictegravir, emtricitabine, and tenofovir alafenamide group and 273 (

130 patients (n=290 of 314) in the bictegravir, emtricitabine, and tenofovir alafenamide group and 93.0%

131 articipants in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group and one (

132 participant in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group did not r

133 ) of 438 in participants in the rilpivirine, emtricitabine, and tenofovir alafenamide group experienc

134 rted for no participants in the bictegravir, emtricitabine, and tenofovir alafenamide group versus fi

135 eight [7%]) in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group; and bron

136 (four [4%] in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group; and one

137 The coformulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently be

138 ose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-infected

139 proxil fumarate to elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologicall

140 ose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is a once-daily

141 le-tablet regimen consisting of bictegravir, emtricitabine, and tenofovir alafenamide is recommended

142 The elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen was wel

143 Exposures to the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen were si

144 ss frequently in patients given bictegravir, emtricitabine, and tenofovir alafenamide than in those g

145 tudy drug were less common with bictegravir, emtricitabine, and tenofovir alafenamide than with dolut

146 emonstrating non-inferiority of bictegravir, emtricitabine, and tenofovir alafenamide to dolutegravir

147 gle-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continui

148 1), and six (2%) of 320 in the bictegravir, emtricitabine, and tenofovir alafenamide versus six (2%)

149 ose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide was efficacious

150 At week 96, bictegravir, emtricitabine, and tenofovir alafenamide was non-inferio

151 INTERPRETATION: Switching to rilpivirine, emtricitabine, and tenofovir alafenamide was non-inferio

152 At week 144, bictegravir, emtricitabine, and tenofovir alafenamide was non-inferio

153 o phase 3 studies, coformulated bictegravir, emtricitabine, and tenofovir alafenamide was non-inferio

154 Bictegravir, emtricitabine, and tenofovir alafenamide was safe and we

155 The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide was safe and we

156 Exposures to elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide were higher, bu

157 ine) and 645 in study 2 (327 to bictegravir, emtricitabine, and tenofovir alafenamide, 325 to doluteg

158 and treated in study 1 (314 to bictegravir, emtricitabine, and tenofovir alafenamide, and 315 to dol

159 ndomly assigned (1:1) adults to bictegravir, emtricitabine, and tenofovir alafenamide, or dolutegravi

160 on of therapy with elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (combin

161 d (1:1) to receive elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integr

162 regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compare

163 (HIV-1 RNA <50 copies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at

164 HIV-1 RNA <50 copies per mL) on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate for at

165 pared with 45 (10%) of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group.

166 e, and tenofovir alafenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non

167 ing a regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.

168 ed with remaining on coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

169 mide compared with remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate.

170 1 genotype with sensitivity to elvitegravir, emtricitabine, and tenofovir.

171 We investigated whether tenofovir and emtricitabine are excreted into breast milk and then abs

172 ludes oral tenofovir disoproxil fumarate and emtricitabine as an option.

173 on to oral tenofovir disoproxil fumarate and emtricitabine as compared with oral PrEP alone.

174 including coformulation with rilpivirine and emtricitabine, as initial and ongoing treatment for HIV-

175 mg (DOR/3TC/TDF) or to efavirenz at 600 mg, emtricitabine at 200 mg, and TDF at 300 mg (EFV/FTC/TDF)

176 and EVGcobi, associated to tenofovir-DF and emtricitabine, behave similarly and achieve an undetecta

177 ples were collected to measure tenofovir and emtricitabine concentrations (a measure of adherence and

178 Tenofovir and emtricitabine concentrations were quantified using liqui

179 s high incidence population, daily tenofovir-emtricitabine conferred even higher protection against H

180 h participants initiated PrEP with tenofovir/emtricitabine during very early Fiebig stage I (detectab

181 viral therapy with elvitegravir, cobicistat, emtricitabine (E/C/F) and tenofovir disoproxil fumarate

182 n individuals prescribed primarily tenofovir/emtricitabine/efavirenz in rural KwaZulu-Natal within a

183 Dual-class PDR to a mainly tenofovir/emtricitabine/efavirenz regimen was associated with poor

184 , mostly on fixed-dose combination tenofovir/emtricitabine/efavirenz, presence of both nonnucleoside

185 th elvitegravir (EVG, E), cobicistat (C) and emtricitabine (F), a recommended antiretroviral regimen,

186 h elvitegravir (EVG; E), cobicistat (C), and emtricitabine (F), a recommended antiretroviral regimen,

187 Tenofovir alafenamide-emtricitabine (F/TAF) was recently approved as a noninfe

188 er option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (P

189 For emtricitabine, FGT:plasma was significantly lower in par

190 daily oral tenofovir disoproxil fumurate and emtricitabine for HIV PrEP, quarterly HIV and STI testin

191 people taking tenofovir disoproxil fumarate/emtricitabine for HIV prevention.

192 ompleted trial of tenofovir alafenamide plus emtricitabine for PrEP.

193 PrEP) with tenofovir disoproxil fumarate and emtricitabine for the prevention of HIV infection is rol

194 f tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg among adults living with huma

195 we compared a triple-therapy combination of emtricitabine (FTC) and DTG plus either of two tenofovir

196 Oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are effective in HIV-1 pre-exposure

197 ther TAF alone or the combination of TAF and emtricitabine (FTC) can prevent vaginal infection.

198 estigated whether the combination of TAF and emtricitabine (FTC) could prevent simian/human immunodef

199 dministrated tenofovir alafenamide (TAF) and emtricitabine (FTC) loaded nanoparticles (NPs) to soluti

200 n of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or placebo before and after sexual a

201 In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) in hu

202 184V/I cause high-level lamivudine (3TC) and emtricitabine (FTC) resistance and increased tenofovir d

203 184V/I cause high-level lamivudine (3TC) and emtricitabine (FTC) resistance, and increased tenofovir

204 oside reverse transcriptase inhibitor (NRTI) emtricitabine (FTC), and injectable aqueous nanodispersi

205 olled trial of daily oral TDF, alone or with emtricitabine (FTC), in HIV-uninfected African men and w

206 d, comparing 4 regimens: MVC alone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumar

207 MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (

208 he NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, ab

209 retroviral therapy (cART) switching to DTG + emtricitabine (FTC).

210 eceiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/EFV 600 mg with a viral load (VL) <5

211 decreases the prophylactic efficacy of oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

212 f antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) provide little structural evid

213 g antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP), we structurally reveal the co

214 il fumarate [TDF] or DOR [100 mg daily] with emtricitabine [FTC]/TDF or abacavir [ABC]/3TC [n = 747])

215 Tenofovir/emtricitabine HIV prevention trials among women in Afric

216 The inclusion of lamivudine or emtricitabine in cART did not influence the time to viro

217 mivudine, the use of tenofovir-lamivudine or emtricitabine in combination with nevirapine was a stron

218 steady-state concentrations of tenofovir and emtricitabine in infant plasma ingested via breastfeedin

219 ART) for HIV/HBV (tenofovir, lamivudine, and emtricitabine) in a large cohort encompassing heterosexu

220 onotherapy or a combination of tenofovir and emtricitabine) in HIV serodiscordant couples aged 18 yea

221 osure prophylaxis (PrEP) with oral tenofovir/emtricitabine is an effective means of decreasing human

222 in the form of tenofovir-disoproxil-fumarate/emtricitabine is being implemented in selected sites in

223 Daily tenofovir disoproxil fumarate/emtricitabine is recommended for use as preexposure prop

224 mbination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immunodeficiency vi

225 tions, combined with elvitegravir/cobicistat/emtricitabine, maintained HIV-1 RNA suppression in semen

226 formulated tenofovir disoproxil fumarate and emtricitabine once a day (atazanavir group).

227 os(t)ides (tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine) and with no re

228 HIV-infected patients on EFV plus tenofovir/emtricitabine or abacavir/lamivudine with NAFLD were ran

229 troviral therapy (ART) with either tenofovir-emtricitabine or lamivudine (tenofovir group) or zidovud

230 ed darunavir plus raltegravir plus tenofovir-emtricitabine or tenofovir plus lamivudine), and D (best

231 avir, raltegravir, and either tenofovir plus emtricitabine or tenofovir plus lamivudine), C (ritonavi

232 Despite sparse efficacy data, tenofovir-emtricitabine or tenofovir-lamivudine plus nevirapine is

233 each with tenofovir disoproxil fumarate and emtricitabine orally once daily, for up to 96 weeks.

234 randomized to tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/riton

235 were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavi

236 cal trial (HPTN 067/ADAPT) of oral PrEP with emtricitabine plus tenofovir disoproxil fumarate at a re

237 ommendations for daily use of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate in wome

238 ovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleoside reverse transcripta

239 y (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD

240 Reactive nitrogen species also reacted with emtricitabine, propranolol, and other trace organic cont

241 ated by hair concentrations of tenofovir and emtricitabine (ptrend=0.008).

242 e-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection.

243 nofovir and 183.0 ng/mL (113.0 to 250.0) for emtricitabine, reflecting trough-to-peak breast milk con

244 cy of oral tenofovir disoproxil fumarate and emtricitabine relies on optimal adherence, which poses a

245 breast milk concentrations of tenofovir and emtricitabine (respective median trough-to-peak concentr

246 tion ratios of 1.0 for tenofovir and 0.8 for emtricitabine, respectively.

247 antivirals, including tenofovir alafenamide, emtricitabine, sofosbuvir, ledipasvir, and velpatasvir w

248 or-associated resistance that led to reduced emtricitabine susceptibility.

249 ablets and tenofovir disoproxil fumarate and emtricitabine tablets were over-encapsulated to visually

250 Emtricitabine/TAF provided a level of protection against

251 f doses of tenofovir disoproxil fumarate and emtricitabine taken per week, as estimated by hair conce

252 ral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) for preexposure prophylaxis (PrE

253 a approved tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) co-formulate for use in pre-expo

254 worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licensed for ad

255 -based regimens with a backbone of tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC)

256 The patients were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r

257 r disoproxil fumarate (TDF) and dolutegravir/emtricitabine/TDF arms.

258 tenofovir alafenamide, 325 to dolutegravir, emtricitabine, tenofovir alafenamide).

259 nd no history of resistance to elvitegravir, emtricitabine, tenofovir alafenamide, or tenofovir.

260 was non-inferior to continuing rilpivirine, emtricitabine, tenofovir disoproxil fumarate in maintain

261 enofovir alafenamide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate).

262 ; screening genotypes showing sensitivity to emtricitabine, tenofovir, lamivudine, and abacavir; and

263 We evaluated an elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regime

264 e short-term, open-label study of daily oral emtricitabine-tenofovir disoproxil fumarate PrEP among 5

265 this decade from pivotal studies using oral emtricitabine-tenofovir disoproxil fumarate.

266 CT03227861) study using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/

267 CT03227861) study using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/

268 nd pibrentasvir with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, abacavir/dolutegrav

269 2%-99.3%) and similar to that seen with oral emtricitabine/tenofovir disoproxil fumarate (94.0%; 55.1

270 Background therapies were emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in

271 e ADVANCE study randomized to the efavirenz /emtricitabine/tenofovir disoproxil fumarate (TDF) and do

272 prospective, open-label study of rilpivirine/emtricitabine/tenofovir disoproxil fumarate in ART-naive

273 -equivalent doses of CAB LA, 6 received oral emtricitabine/tenofovir disoproxil fumarate, and 10 were

274 e BMD loss seen with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate.

275 ritonavir, lopinavir/ritonavir, or efavirenz/emtricitabine/tenofovir disoproxil fumarate.

276 ed-glycerin (RG) 1% tenofovir (TFV) and oral emtricitabine/TFV disoproxil fumarate (FTC/TDF).

277 mucosal tissue concentrations of tenofovir, emtricitabine, their active metabolites (tenofovir dipho

278 ng ART with atazanavir/ritonavir + tenofovir/emtricitabine to a single zoledronic acid (ZOL) infusion

279 fovir and 31.9 mug/kg (IQR 21.0 to 60.8) for emtricitabine, translating into a <0.01% and 0.5% relati

280 sition of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in the FGT have been

281 tabolites (tenofovir diphosphate [TFVdp] and emtricitabine triphosphate [FTCtp], respectively), and c

282 abine + a third agent or switch to tenofovir/emtricitabine (TRULIGHT trial).

283 veness of tenofovir disoproxil fumarate plus emtricitabine varies across populations; thus, similar H

284 PrEP) with tenofovir disoproxil fumarate and emtricitabine was adopted by WHO as a strategy to reduce

285 monotherapy or tenofovir disoproxil fumarate/emtricitabine was associated with decreased risk of acqu

286 s unquantifiable in 46/49 samples (94%), but emtricitabine was detectable in 47/49 (96%) (median [IQR

287 Emtricitabine was negatively associated with noncalcifie

288 rt taking daily oral co-formulated tenofovir/emtricitabine, we examined the prevalence and duration o

289 fant plasma concentrations for tenofovir and emtricitabine were 12,500 and >200-fold lower than the r

290 ssigned (1:1) to switch to fixed-dose 200 mg emtricitabine with 10 mg or 25 mg tenofovir alafenamide

291 tenofovir alafenamide or to continue 200 mg emtricitabine with 200 mg or 300 mg tenofovir disoproxil

292 With its safety advantages, fixed-dose emtricitabine with tenofovir alafenamide has the potenti

293 afety and efficacy of fixed-dose combination emtricitabine with tenofovir alafenamide in patients swi

294 tabine with tenofovir disoproxil fumarate to emtricitabine with tenofovir alafenamide, high rates of

295 Emtricitabine with tenofovir disoproxil fumarate is a st

296 In patients switching from emtricitabine with tenofovir disoproxil fumarate to emtr

297 ofovir alafenamide in patients switched from emtricitabine with tenofovir disoproxil fumarate.

298 g regimens containing fixed-dose combination emtricitabine with tenofovir disoproxil fumartate from 7

299 oval mechanism for abacavir, zidovudine, and emtricitabine, with half-lives (t1/2,photo) in wetland w

300 to-2-week postpartum "tail" of tenofovir and emtricitabine (zidovudine alone); zidovudine, lamivudine